Home › Trial NCT04837508
A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
- Trial IDNCT04837508
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorShanghai Miracogen Inc.
- Enrollment86
- Start date2021-06-07
- ConditionsAdvanced or Metastatic Biliary Tract Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.